NEW YORK ─ Investment bank Evercore ISI on Monday initiated coverage of point-of-care testing company LumiraDx with an Outperform rating and a price target of $20 per share.
In a research note, Evercore ISI analyst Vijay Kumar said LumiraDx "has the legs to sustain" among numerous point-of-care companies entering the market for SARS-CoV-2 diagnostic testing.
The company "promises central lab accuracy at [the point of care] at a compelling price point," he said, adding that the testing company differentiates itself from competitors with "the potential to do both antigen testing and MDx tests on the same test strip [with a very low cost of goods sold on] a portable, ultralight instrument."
The company's core management team "has worked together for more than a decade and has had multiple, successful exits," Kumar wrote.
Among the most important risks for LumiraDx is whether it can "gain traction in the market given proliferation of POC testing solutions, and potential manufacturing /quality issues," he added.
The London-based diagnostics company went public on the Nasdaq in September after announcing the closing of its previously announced merger with CA Healthcare Acquisition, a special purpose acquisition company.
In October, BTIG initiated coverage of LumiraDx with a Buy rating and a price target of $12 on its shares.